Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Diabetes Mellitus, Insulin-Dependent, 12 × tremelimumab × Clear all

Phase

Phase 2 4 Phase 1 3 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 4 Carcinoma, Non-Small-Cell Lung 3 Urinary Bladder Neoplasms 2 Small Cell Lung Carcinoma 2 Liver Neoplasms 2 Urothelial Cancer 1 Recurrence 1 Non Small Cell Lung Cancer NSCLC 1 Non - Small Cell Lung Cancer NSCLC 1 Melanoma 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Carcinoma, Renal Cell 1 Carcinoma 1

Interventions

Ipilimumab 3 tremelimumab 1 tilsotolimod 1 spartalizumab 1 pembrolizumab 1 durvalumab 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03084471 2022-12-22

STRONG

AstraZeneca

Phase 3 Completed

867 enrolled 10 charts

Diabetes Mellitus, Insulin-Dependent, 12

Data powered by HemOnc (CC BY 4.0) Colophon ⚡